Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, First-In-Human, Multicenter, Open-Label, Study of GQ1001, a HER2 Targeted Antibody-Drug Conjugate, Administered Intravenously, in Adult Patients With HER2-Positive Advanced Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Eligible patients will be assigned to receive GQ1001, an antibody drug conjugate, intravenously, every 21-Days. GQ1001 will be administered at various doses, starting at 1.2mg/kg, through to 2.4mg/kg, 3.6mg/kg, 4.8mg/kg and 6.0mg/kg.